Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50-Day Moving Average – What’s Next?

09 Apr 2026, 02:42 by Michael Walen · The Markets Daily

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.35 and traded as high as $2.61. Spero Therapeutics shares last traded at $2.61, with a volume of 478,730 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SPRO shares. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

View Our Latest Report on SPRO

Spero Therapeutics Trading Up 1.9%

The business has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.34. The company has a market cap of $157.46 million, a price-to-earnings ratio of 22.67 and a beta of 1.45.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.73. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.The company had revenue of $41.30 million during the quarter, compared to the consensus estimate of $26.00 million. On average, analysts anticipate that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 87,917 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the sale, the insider owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. This represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GSK plc acquired a new stake in shares of Spero Therapeutics during the 4th quarter valued at $21,414,000. Vanguard Group Inc. lifted its holdings in shares of Spero Therapeutics by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after purchasing an additional 39,474 shares in the last quarter. State Street Corp lifted its holdings in shares of Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after purchasing an additional 19,200 shares in the last quarter. Ionic Capital Management LLC lifted its holdings in shares of Spero Therapeutics by 39.2% in the third quarter. Ionic Capital Management LLC now owns 208,725 shares of the company’s stock valued at $392,000 after purchasing an additional 58,725 shares in the last quarter. Finally, Intrepid Family Office LLC lifted its holdings in shares of Spero Therapeutics by 50.0% in the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock valued at $384,000 after purchasing an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.